ORIC Pharmaceuticals, Inc. (FRA:4TZ)

Market Cap	1.05B +108.7%
Revenue (ttm)	n/a
Net Income	-110.27M
EPS	-1.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	10.70
Previous Close	9.65
Day's Range	10.70 - 10.70
52-Week Range	3.70 - 13.30
Beta	n/a
RSI	57.48
Earnings Date	May 5, 2026

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 104
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4TZ

Financial Performance

Financial numbers in USD